Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

616 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Refining risk prediction in pediatric acute lymphoblastic leukemia through DNA methylation profiling.
Mosquera Orgueira A, Krali O, Pérez Míguez C, Peleteiro Raíndo A, Díaz Arias JÁ, González Pérez MS, Pérez Encinas MM, Fernández Sanmartín M, Sinnet D, Heyman M, Lönnerholm G, Norén-Nyström U, Schmiegelow K, Nordlund J. Mosquera Orgueira A, et al. Among authors: heyman m. Clin Epigenetics. 2024 Mar 28;16(1):49. doi: 10.1186/s13148-024-01662-6. Clin Epigenetics. 2024. PMID: 38549146 Free PMC article.
Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthøj S, Vettenranta K, Wesenberg F, Saarinen-Pihkala U; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Schmiegelow K, et al. Among authors: heyman m. J Pediatr Hematol Oncol. 2009 Jun;31(6):385-92. doi: 10.1097/MPH.0b013e3181a6e171. J Pediatr Hematol Oncol. 2009. PMID: 19648786 Clinical Trial.
DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia.
Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, Forestier E, Heyman M, Jonmundsson G, Kanerva J, Schmiegelow K, Söderhäll S, Gustafsson MG, Lönnerholm G, Syvänen AC. Milani L, et al. Among authors: heyman m. Blood. 2010 Feb 11;115(6):1214-25. doi: 10.1182/blood-2009-04-214668. Epub 2009 Nov 25. Blood. 2010. PMID: 19965625 Free article.
The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse.
Schmiegelow K, Heyman M, Gustafsson G, Lausen B, Wesenberg F, Kristinsson J, Vettenranta K, Schroeder H, Forestier E, Rosthoej S; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Schmiegelow K, et al. Among authors: heyman m. Leukemia. 2010 Apr;24(4):715-20. doi: 10.1038/leu.2009.303. Epub 2010 Feb 4. Leukemia. 2010. PMID: 20130603 Free article.
In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
Lönnerholm G, Thörn I, Sundström C, Frost BM, Flaegstad T, Heyman M, Jonsson OG, Harila-Saari A, Madsen HO, Porwit A, Schmiegelow K, Söderhäll S, Wesenberg F, Vettenranta K, Larsson R, Forestier E. Lönnerholm G, et al. Among authors: heyman m. Leuk Res. 2011 Apr;35(4):472-8. doi: 10.1016/j.leukres.2010.09.001. Epub 2010 Oct 18. Leuk Res. 2011. PMID: 20961616
The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial.
Zachariadis V, Gauffin F, Kuchinskaya E, Heyman M, Schoumans J, Blennow E, Gustafsson B, Barbany G, Golovleva I, Ehrencrona H, Cavelier L, Palmqvist L, Lönnerholm G, Nordenskjöld M, Johansson B, Forestier E, Nordgren A; Nordic Society of Pediatric Hematology, Oncology (NOPHO); Swedish Cytogenetic Leukemia Study Group (SCLSG). Zachariadis V, et al. Among authors: heyman m. Leukemia. 2011 Apr;25(4):622-8. doi: 10.1038/leu.2010.318. Epub 2011 Jan 18. Leukemia. 2011. PMID: 21242996
616 results